Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
JAMA Health Forum2021Vol. 2(12), pp. e214182–e214182
Citations Over TimeTop 1% of 2021 papers
Lauren A. Eberly, Lin Yang, Utibe R. Essien, Nwamaka D. Eneanya, Howard Julien, Jing Luo, Ashwin S. Nathan, Sameed Ahmed M. Khatana, Elias J. Dayoub, Alexander C. Fanaroff, Jay Giri, Peter W. Groeneveld, Srinath Adusumalli
Abstract
In this cohort study of US patients with T2D, GLP-1 RA use increased, but remained low overall for treatment of T2D, particularly among patients with ASCVD who are likely to derive the most benefit. Asian, Black, and Hispanic patients and those with low income were less likely to receive treatment with a GLP-1 RA. Strategies to lower barriers to GLP-1 RA use, such as lower cost, are needed to prevent the widening of well-documented inequities in cardiovascular disease outcomes in the US.
Related Papers
- → Asthma and ethnic minorities: socioeconomic status and beyond(2009)205 cited
- → Diabetic dermopathy and internal complications in diabetes mellitus(1998)110 cited
- → Ethnicity and Socioeconomic Status as Sources of Participation: The Case for Ethnic Political Culture(1979)53 cited
- [Surgical treatment of tuberculosis and nonspecific lung diseases associated with diabetes mellitus].(1989)
- → P1373Assessment of atrial fibrillation cryoablation outcomes in patients with diabetes(2020)